-
公开(公告)号：US20070248981A1
公开(公告)日：2007-10-25
申请号：US11789169
申请日：2007-04-24
Applicant: James Snider , Sven Jacobson
Inventor： James Snider , Sven Jacobson
CPC classification number: G01N33/6893 , C12Q1/6883 , G01N33/564 , G01N33/6869 , G01N2333/54 , G01N2333/7155 , G01N2800/12 , G01N2800/325 , G01N2800/50 , G01N2800/52 , G01N2800/56 , G06F19/00
Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
Abstract translation: 循环ST2和/或IL-33浓度的测量对于受试者的预后评估是有用的，特别是用于预测不良临床结果，例如死亡率和严重疾病的检测。
-
公开(公告)号：US10203339B2
公开(公告)日：2019-02-12
申请号：US12299177
申请日：2007-05-01
Applicant: James V. Snider , Sven Jacobson
Inventor： James V. Snider , Sven Jacobson
Abstract: This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.
-
3.发明授权公开(公告)号：US08858997B2
公开(公告)日：2014-10-14
申请号：US13610335
申请日：2012-09-11
Applicant: Sven Jacobson
Inventor： Sven Jacobson
IPC: A61K47/10 , A61K9/10 , A61K9/00 , A61K31/64 , A61K31/451 , A61K9/16 , A61K31/175 , A61K9/19
CPC classification number: A61K9/1682 , A61K9/0019 , A61K9/1611 , A61K9/1623 , A61K9/19 , A61K31/175 , A61K31/451 , A61K31/64 , Y10S514/96
Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
Abstract translation: 本发明提供组合物，冻干化合物和制备药物组合物的方法，以及提供化合物溶液和冻干制剂的试剂盒。 组合物，方法和试剂盒在涉及在低pH值和中等pH值下具有低溶解度的治疗剂的药物应用中特别有用。 某些实施方案提供了在液体溶液中冻干化合物的方法，其包括以下步骤：a）在不存在缓冲液的情况下制备目的化合物的水溶液; b）将pH调节至高的pH值，以增加目标化合物的溶解度; 和c）冷冻干燥该溶液以提供冻干固体组合物。 还公开了包括缓冲液的水溶液。 提供冻干制剂，包括微粉化和非微粉化粉末。
-
公开(公告)号：US20070202155A1
公开(公告)日：2007-08-30
申请号：US11701964
申请日：2007-02-01
Applicant: Robert Ang , Ludwig Weimann , Sven Jacobson
Inventor： Robert Ang , Ludwig Weimann , Sven Jacobson
CPC classification number: A61K9/7061 , A61K31/21 , A61K47/10
Abstract: The present invention is drawn to a transdermal patch for the delivery of a nitroglycerin or other NO donor. The patch can comprise a backing layer, and a nitroglycerin-containing composition or other NO donor-containing composition which is supported at least in part by the backing layer. The transdermal patch can have a drug delivery zone defined by the area where the composition contacts an intact human skin site, and the transdermal patch can be formulated to deliver a nitric oxide donor, such as nitroglycerin, at from about 5 μg/hour to about 70 μg/hour. In one embodiment, the transdermal patch can provide a delivery rate at the drug delivery zone of from about 1 μg/cm2/day to about 600 μg/cm2/day. In another embodiment, the transdermal patch can contain from 6 wt % to 18 wt % of the nitric oxide donor, e.g., nitroglycerin. In each embodiment, the patch can contain at least 450 μg/cm2 of nitroglycerin.
Abstract translation: 本发明涉及用于递送硝酸甘油或其他NO供体的透皮贴片。 贴片可以包含背衬层和含硝酸甘油的组合物或其它含NO供体的组合物，其至少部分由背衬层支撑。 透皮贴剂可以具有由组合物接触完整的人皮肤部位的区域限定的药物递送区，并且透皮贴剂可以配制成以约5mug /小时至约约5ug /小时递送一氧化氮供体，例如硝酸甘油 70杯/小时。 在一个实施方案中，透皮贴剂可以在药物递送区域提供约1mug / cm 2 /天至约600mug / cm 2 /天的输送速率 。 在另一个实施方案中，透皮贴剂可含有6重量％至18重量％的一氧化氮供体，例如硝酸甘油。 在每个实施方案中，贴片可以含有至少450杯/平方厘米的硝酸甘油。
-
5.发明申请Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents 审中-公开使用透皮一氧化氮发生剂治疗过度使用性腱鞘炎公开(公告)号：US20060286158A1
公开(公告)日：2006-12-21
申请号：US11366204
申请日：2006-03-01
Applicant: George Calvert Murrell , Robert Ang , Ludwig Weimann , Sven Jacobson
Inventor： George Calvert Murrell , Robert Ang , Ludwig Weimann , Sven Jacobson
CPC classification number: A61K9/7023 , A61K31/21
Abstract: The present invention provides methods for treating tendinopathy in the absence of inflammation by the transdermal administration of nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies, and the use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr.
Abstract translation: 本发明提供通过透皮给药硝酸甘油来治疗不存在炎症的腱鞘炎的方法。 这样的方法包括减轻与这种腱病相关的疼痛的方法，以及使用经皮贴片，其配置为以5mcg / hr至约85mcg / hr的速率递送三硝酸甘油酯。
-
Patent Agency Ranking
公开(公告)号：US09568481B2
公开(公告)日：2017-02-14
申请号：US13282111
申请日：2011-10-26
Applicant: James V. Snider , Sven Jacobson
Inventor： James V. Snider , Sven Jacobson
IPC: G01N33/68 , C12Q1/68 , G01N33/564
CPC classification number: G01N33/6893 , C12Q1/6883 , G01N33/564 , G01N33/6869 , G01N2333/54 , G01N2333/7155 , G01N2800/12 , G01N2800/325 , G01N2800/50 , G01N2800/52 , G01N2800/56 , G06F19/00
Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
Abstract translation: 循环ST2和/或IL-33浓度的测量对于受试者的预后评估是有用的，特别是用于预测不良临床结果，例如死亡率和严重疾病的检测。
-
公开(公告)号：US20130245069A1
公开(公告)日：2013-09-19
申请号：US13610335
申请日：2012-09-11
Applicant: Sven Jacobson
Inventor： Sven Jacobson
IPC: A61K9/16 , A61K31/451 , A61K31/64
CPC classification number: A61K9/1682 , A61K9/0019 , A61K9/1611 , A61K9/1623 , A61K9/19 , A61K31/175 , A61K31/451 , A61K31/64 , Y10S514/96
Abstract: The present invention provides compositions, methods for lyophilizing compounds and making pharmaceutical compositions, and kits providing solutions and lyophilized formulations of compounds. The compositions, methods, and kits are particularly useful in pharmaceutical applications involving therapeutic agents that have low solubility at low pH and medium pH values. Certain embodiments provide methods for lyophilizing compounds in liquid solutions, which include the steps of: a) preparing aqueous solutions of a compound of interest in the absence of buffer; b) adjusting the pH to high values of pH in order to increase the solubility of the compound of interest; and c) freeze-drying the solution to provide a lyophilized solid composition. Aqueous solutions including buffer are also disclosed. Lyophilized formulations, including micronized and non-micronized powders, are provided.
-
公开(公告)号：US20100009356A1
公开(公告)日：2010-01-14
申请号：US12299177
申请日：2007-05-01
Applicant: James V. Snider , Sven Jacobson
Inventor： James V. Snider , Sven Jacobson
CPC classification number: G01N33/6869 , G01N33/6893 , G01N2333/7155 , G01N2800/226 , G01N2800/32 , G01N2800/325 , G01N2800/52
Abstract: This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function.
Abstract translation: 本发明涉及用于检测高体重指数（BMI）个体的心血管疾病例如急性冠状动脉综合征，心力衰竭和/或肺栓塞的方法，例如BMI为25-29或30或更高 ，肾功能受损者。
-
9.发明申请INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASE 审中-公开用于诊断和预防心血管疾病的白细胞介素-33（IL-33）公开(公告)号：US20090305265A1
公开(公告)日：2009-12-10
申请号：US12298613
申请日：2007-04-27
Applicant: James V. Snider , Sven Jacobson
Inventor： James V. Snider , Sven Jacobson
CPC classification number: C12Q1/6883 , G01N33/6869 , G01N2800/32 , Y10T436/143333
Abstract: The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pancarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis).
Abstract translation: 本发明包括在诊断包括急性冠状动脉综合征（ACS），心肌梗死和/或心力衰竭，心绞痛，心脏肥大，动脉硬化，心肌炎，全脑功能障碍的心血管疾病中使用白细胞介素-33（IL-33） ，心内膜炎，中风和/或肺栓塞以及这些病症（预后）的严重程度的确定。
-
10.发明申请Treatment of persistent active tendinopathy using transdermal glyceryl trinitrate providing durability of effect 审中-公开使用透皮甘油三硝酸酯治疗持续性活动性腱膜，提供耐久性公开(公告)号：US20060286159A1
公开(公告)日：2006-12-21
申请号：US11446571
申请日：2006-06-01
Applicant: George Calvert Murrell , Robert Ang , Sven Jacobson , David Geliebter
Inventor： George Calvert Murrell , Robert Ang , Sven Jacobson , David Geliebter
CPC classification number: A61K9/0014 , A61K9/7023 , A61K31/21
Abstract: The present invention provides methods for treating tendinopathy providing a durability of effect by administering nitroglycerin. Such methods include methods for relieving pain associated with such tendinopathies. The use of a transdermal patch configured to deliver glyceryl trinitrate at a rate of 5 mcg/hr to about 85 mcg/hr
Abstract translation: 本发明提供通过施用硝酸甘油来治疗提供耐久性的腱鞘的方法。 这些方法包括减轻与这种腱病相关的疼痛的方法。 使用透皮贴片，其被配置成以5mcg / hr的速率将硝酸甘油酯输送至约85mcg / hr
-
-
-
-
-
-
-
-
-
Search Results
22
records
(took 0.022 seconds)
